Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Expert Rev Clin Pharmacol. 2021 Jul 15;14(10):1253–1266. doi: 10.1080/17512433.2021.1949287

Figure 1.

Figure 1.

Simplified schematic of the biological effect of CTLA4 and PD1 blockade. Antibodies targeting CTLA4 remove negative regulation of T cell priming in the lymph node and can lead to depletion of Tregs in tumors. Antibodies targeting the PD1 pathway remove negative regulation of T cell activation in tumors and can lead to depletion of Tregs and MDSCs. (Adapted from “Blockade of CTLA-4 or PD-1 Signaling in Tumor Immunotherapy”, by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates).